Pemigatinib for Previously Treated Metastatic or Unresectable Central Nervous System Tumors with FGFR Mutations or Rearrangements: FIGHT-207 Results.

Fiche publication

Date publication

octobre 2025

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HERVIEU Alice

Tous les auteurs :
Spanggaard I, Matrana M, Lima CR, Mahipal A, Vieito M, Hervieu A, Goyal L, Rodón J, Veronese ML, Oliveira N, Li X, Schaffer M, Kesari S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41100064

Résumé

Central nervous system (CNS) tumors often harbor alterations in genes regulating key cellular pathways, including fibroblast growth factor receptor (FGFR) genes. Here we report the efficacy and safety of treatment with pemigatinib, an oral, potent, selective FGFR1-3 inhibitor, in patients with advanced FGFR-altered CNS tumors. FIGHT-207 was a single-arm, open-label, phase 2 study of pemigatinib in patients with advanced solid tumors harboring FGFR fusions/rearrangements or other mutations. Patients received pemigatinib 13.5 mg once daily until disease progression or unacceptable toxicity. Endpoints included tumor response and safety. Of the 13 patients with CNS tumors in FIGHT-207, 10 had glioblastoma. FGFR alterations were FGFR3-TACC3 fusions (n = 9), FGFR1 K656E mutations (n = 2), FGFR1 N546K mutation (n = 1), and FGFR1-MITF fusion (n = 1). Three patients (23%) displayed objective responses (1 complete, 2 partial). Safety was consistent with the overall FIGHT-207 population. Pemigatinib had antitumor activity and a manageable safety profile in patients with CNS tumors.